Bicalutamide (CDX)
SIGMA/B9061 - ≥98% (HPLC), powder
Synonym: Casodex; Cosudex; N-
CAS Number: 90357-06-5
Empirical Formula (Hill Notation): C18H14F4N2O4S
Molecular Weight: 430.37
MDL Number: MFCD00869971
Linear Formula: C18H14F4N2O4S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | powder |
| InChI | 1S/C18H14F4N2O4S/c1-17(26 |
| InChI key | LKJPYSCBVHEWIU-UHFFFAOYSA |
| originator | AstraZeneca |
| Quality Level | 100 ![]() |
| SMILES string | CC(O)(CS(=O)(=O)c1ccc(F)c |
| solubility | DMSO: >5 mg/mL |
| H2O: insoluble | |
| storage condition | desiccated |
| protect from light |
| Application: | Bicalutamide (CDX) has been used as an androgen receptor (AR) antagonist in prostate, bladder cancer cell lines and human fetal skeletal muscle cells. It has also been used as a supplement in RPMI 1640 for culturing androgen-independent LNCaP (LNCaP-AI) cell line. |
| Biochem/physiol Actions: | Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) Antagonist and a pure antiandrogen. |
| Biochem/physiol Actions: | Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) antagonist and a pure antiandrogen. It acts via balancing histone acetylation/deacetylation and recruitment of coregulators. Bicalutamide (CDX) abolishes androgen-mediated expression. For example, MMP13 upregulation in prostate cancer, PLZF (promyelocytic leukemia zinc finger protein), and GADD45γ (growth arrest and DNA damage inducible, gamma). Bicalutamide (CDX) is inhibited by non-genomic, transcription-independent stimulation of PI3K/AKT phosphorylation by androgens. |
| Features and Benefits: | This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Features and Benefits: | This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by AstraZeneca . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol | ![]() GHS08,GHS09 |
| Signal word | Danger |
| Hazard statements | H351 - H360FD - H410 |
| Precautionary statements | P202 - P273 - P280 - P308 + P313 - P391 - P405 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |



